Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $50 million public offering of its common stock, with underwriters receiving a 30-day option for an additional 15% of shares. The offering is reliant on market conditions and other factors, with no guarantee of completion or specified terms. BofA Securities, Jefferies, Barclays, and Raymond James are managing the offering, with preliminary documentation to be submitted to the SEC. Tarsus aims to utilize the proceeds to advance its therapies, including TP-03 for eye care and TP-05 for Lyme disease prevention.

Tarsus Pharmaceuticals announced positive results from the Saturn-2 Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for treating Demodex blepharitis. The trial met its primary endpoint, with 56% of patients achieving complete collarette cure, compared to 13% on the vehicle. Secondary endpoints showed significant improvements in mite eradication and complete lid erythema cure. TP-03 also demonstrated a favorable safety profile. Tarsus plans to submit a New Drug Application to the FDA in the second half of 2022, potentially benefiting 25 million U.S. patients.

Tarsus Pharmaceuticals (NASDAQ: TARS) will host a webcast on May 2, 2022, at 5:00am PT to discuss the topline results from the Saturn-2 Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for treating Demodex blepharitis. This trial is part of Tarsus's mission to revolutionize treatment in eye care with innovative therapies. In addition to TP-03, the company is advancing other investigational medicines targeting high unmet needs in eye care and infectious disease prevention. The webcast will be available for 90 days post-event.

Tarsus Pharmaceuticals (NASDAQ: TARS) presented significant findings at the ASCRS 2022 Annual Meeting, highlighting the substantial impact of Demodex blepharitis on patients' daily lives. The Atlas Continuation study revealed ongoing challenges for patients, while the Pandora study focused on bacterial counts. CEO Bobak Azamian emphasized the urgent need for effective treatment options as the company prepares to share topline results from the pivotal Saturn-2 trial for TP-03, an investigational treatment targeting Demodex mites, which currently has no FDA-approved solutions.

Tarsus Pharmaceuticals (NASDAQ: TARS) reported substantial advancements in its pipeline, particularly for TP-03, targeting Demodex blepharitis, with pivotal Saturn-2 trial data expected in April 2022 and NDA submission planned within the year. The company completed enrollment in this trial, following successful results from the Saturn-1 trial. Tarsus holds $171.8 million in cash as of December 31, 2021, ensuring a cash runway into the second half of 2024. The firm also advanced TP-05 for Lyme disease and secured a $175 million non-dilutive credit facility, enhancing financial flexibility and growth potential.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in two major healthcare conferences on March 16, 2022. The company will engage in a virtual fireside chat at the Oppenheimer’s 32nd Annual Healthcare Conference at 9:40am PT and a corporate presentation at the Barclays Global Healthcare Conference at 1:50pm PT. Tarsus focuses on innovative treatments in eye care and other therapeutic categories, with investigational products in clinical trials addressing significant unmet needs. Live webcasts will be available on their website.

Tarsus Pharmaceuticals has appointed Dr. José Trevejo as Chief Medical Officer, bringing over 20 years of clinical development experience. This strategic move aims to advance TP-03, Tarsus' investigational treatment for Demodex blepharitis, with an NDA submission anticipated later this year. Dr. Trevejo's expertise in drug development and infectious diseases is expected to enhance Tarsus' pipeline across various therapeutic areas. The company is currently conducting its second pivotal trial for TP-03, while also developing TP-05 for Lyme disease prevention.

Tarsus Pharmaceuticals (NASDAQ: TARS) is hosting a live webcast on February 8, 2022, at 9 a.m. PT, focusing on Demodex blepharitis and its investigational treatment TP-03. Expert speakers include CEO Bobak Azamian and leading ophthalmologists Eric Donnenfeld, Paul Karpecki, and Elizabeth Yeu. The agenda includes insights into the prevalence of Demodex blepharitis, clinical data for TP-03, and a Q&A session. TP-03, an anti-parasitic solution, has shown promise in clinical trials and targets a significant unmet need in eye care.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced the completion of enrollment for its pivotal Phase 3 trial, Saturn-2, evaluating TP-03 for Demodex blepharitis, with 408 patients participating. Topline results are expected in April 2022, with plans for a New Drug Application (NDA) submission if results are favorable. Additionally, Tarsus secured a $175 million non-dilutive credit facility from Hercules Capital and Silicon Valley Bank, enhancing its financial flexibility. This funding supports the advancement of TP-03 and the company's business growth.